| | |
Patients (N = 208)
|
n
|
|---|
|
Age (y/o)
|
Median 69 (48–90)
| | |
| |
Age ≤ 60
|
12.5%
|
26
|
| |
60 < Age ≤ 70
|
46.2%
|
96
|
| |
Age > 70
|
41.3%
|
86
|
|
Race
|
White
|
54.8%
|
114
|
| |
Black
|
38.0%
|
79
|
| |
Other
|
7.2%
|
15
|
|
Charlson Comorbidity Index
|
CCI = 0
|
68.3%
|
142
|
| |
CCI = 1
|
22.6%
|
47
|
| |
CCI ≥ 2
|
9.1%
|
19
|
|
Body Mass Index (BMI)
|
Median 27.34 (15.02-44.96)
| | |
| |
BMI ≥ 30
|
29.3%
|
61
|
|
Partner Status
|
Married or Partnered
|
76.4%
|
159
|
| |
Not Partnered
|
23.6%
|
49
|
|
Employment Status
|
Working
|
47.6%
|
99
|
| |
Not Working
|
52.4%
|
109
|
|
Median Prostate Volume (cc)
|
Median 38.6 (11.6-138.7) cc
| |
208
|
|
Baseline AUA Score
|
Median 7 (0 – 34)
| |
141
|
|
Procedure for BPH
| |
11.5%
|
24
|
|
α
1A
inhibitor usage
| |
27.4%
|
57
|
|
Anticoagulant usage
| |
32.2%
|
67
|
|
Risk Groups (D’Amico’s)
|
Low
|
39.4%
|
82
|
| |
Intermediate
|
52.4%
|
109
|
| |
High
|
8.2%
|
17
|
|
ADT
| |
14.4%
|
30
|
|
SBRT Dose
|
36.25 Gy
|
87.5%
|
182
|
| |
35 Gy
|
12.5%
|
26
|
